Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Trialtrove is the industry's go-to resource to support and inform clinical trial strategy, design and execution. Our expert analysts extract key protocol details, including study objectives, endpoints and inclusion/exclusion criteria, to help you plan for success.
We also monitor trials throughout their life cycle, providing insights into trial timing benchmarks, enrollment successes and failures, accrual details and study results.
Trialtrove incorporates industry-relevant search terms such as our proprietary patient segments, trial outcomes and biomarker tags, so that you can quickly drill down into the targeted information you need.
|Improve your protocol development by analyzing current trends in trial designs and outcomes|
|Identify relevant historical trials with actual enrollment and treatment data to benchmark against|
|Understand the clinical strategies your competitors are using|
|Gain in-depth insight into the global trial landscape and competitive trends by disease|
Trialtrove uses over 58,000 sources to bring you the most comprehensive trial intelligence imaginable.
Don’t waste time combing through onerous trial reports to get the information you need. Trialtrove analysts do the information gathering for you.
With our industry-leading platform you can:
You can also access Trialtrove via our Trials API so you can integrate, connect, and deliver multiple sources of information in real-time.
Trialtrove also offers seamless integration with Sitetrove and Pharmaprojects, our site/investigator and drug development intelligence solutions.
25 Nov 2022
Our annual analysis dissects the data of all Phase I–III clinical trials that started in a year dominated by COVID-19.
We have received your request and we will get back to you soon.